Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 859-867

  Karabela, Sophia P ^a   Psallidas, Ioannis ^a,b   Sherrill, Taylor P ^c   Kairi, Chrysoula A ^a   Zaynagetdinov, Rinat ^c   Cheng, Dong Sheng ^c   Vassiliou, Spyridoula ^d   Mcmahon, Frank ^c   Gleaves, Linda A ^c   Han, Wei ^c   Stathopoulos, Ioannis ^a,e   Zakynthinos, Spyros G ^a   Yull, Fiona E ^c   Roussos, Charis ^a   Kalomenidis, Ioannis ^a,b   Blackwell, Timothy S ^c,f   Stathopoulos, Georgios T ^a,c,e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IASO GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; I KAPPA B; INTERLEUKIN 1BETA; INTERLEUKIN 6; URETHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HISTOLOGY; IMMUNOREACTIVITY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOGENESIS; LUNG LAVAGE; LUNG TUMOR; MOUSE; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; TREATMENT DURATION; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VOLUME; UPREGULATION;

EID: 84859598161     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs024     Document Type: Article

References (46)

1. Jemal, A. et al. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
2. Parkin, D. M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
3. Alberg, A. J. et al. (2007) Epidemiology of lung cancer: aCCP evidencebased clinical practice guidelines (2nd edition). Chest, 132, 29S-55S.
4. Doll, R. et al. (1978) Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J. Epidemiol. Commun. Health, 32, 303-313.
5. Peto, R. et al. (2006) Mortality from Smoking in Developed Countries 1950-2000. Oxford University Press, Oxford, UK. www.ctsu.ox.ac.uk/~tobacco
6. Sun, S. et al. (2007) Lung cancer in never smokers-a different disease. Nat. Rev. Cancer, 7, 778-790.
7. Seow, A. et al. (2006) Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. Carcinogenesis, 27, 1240-1244.
8. Schottenfeld, D. et al. (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin., 56, 69-83.
9. Houghton, A. M. et al. (2008) Common origins of lung cancer and COPD. Nat. Med., 14, 1023-1024.
10. Henschke, C. I. et al. (2006) Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med., 355, 1763-1771.
11. Chaturvedi, A. K. et al. (2010) C-reactive protein and risk of lung cancer. J. Clin. Oncol., 28, 2719-2726.
12. Stathopoulos, G. T. et al. (2007) Epithelial nuclear factor-κB activation promotes urethane-induced lung carcinogenesis. Proc. Natl Acad. Sci. USA, 104, 18514-18519.
13. Meylan, E. et al. (2009) Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature, 462, 104-107.
14. Takahashi, H. et al. (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell, 17, 89-97.
15. Zaynagetdinov, R. et al. (2011) Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene, 2011 Oct 17. doi: 10. 1038/onc. 2011. 480. [Epub ahead of print].
16. Wong, K. K. et al. (2010) NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev. Res. (Phila), 3, 403-405.
17. Inayama, M. et al. (2006) A novel IκB kinase-β inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med., 173, 1016-1022.
18. LeBlanc, R. et al. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res., 62, 4996-5000.
19. Richardson, P. G. et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 348, 2609-2617.
20. Amiri, K. I. et al. (2004) Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res., 64, 4912-4918.
21. Rajkumar, S. V. et al. (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol., 23, 630-639.
22. Tang, X. et al. (2006) Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer, 107, 2637-2646.
23. Psallidas, I. et al. (2010) Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol. Cancer, 9, 56.
24. Fanucchi, M. P. et al. (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small cell lung cancer. J. Clin. Oncol., 24, 5025-5033.
25. Davies, A. M. et al. (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J. Thorac. Oncol., 4, 87-92.
26. Everhart, M. B. et al. (2006) Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J. Immunol., 176, 4995-5005.
27. Nikitin, A. Y. et al. (2004) Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res., 64, 2307-2316.
28. Stathopoulos, G. T. et al. (2008) Zoledronic acid is effective against experimental malignant pleural effusion. Am. J. Respir. Crit. Care Med., 178, 50-59.
29. Stathopoulos, G. T. et al. (2007) Tumor necrosis factor-α promotes malignant pleural effusion. Cancer Res., 67, 9825-9834.
30. Stathopoulos, G. T. et al. (2006) Nuclear factor-κB affects tumor progression in a mouse model of malignant pleural effusion. Am. J. Respir. Cell Mol. Biol., 34, 142-150.
31. Stathopoulos, G. T. et al. (2008) A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J. Natl Cancer Inst., 100, 1464-1476.
32. Greten, F. R. et al. (2007) NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell, 130, 918-931.
33. Di Stefano, A. et al. (2002) Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J., 20, 556-563.
34. Caramori, G. et al. (2003) Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax, 58, 348-351.
35. Stathopoulos, G. T. et al. (2008) Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol. Cancer Res., 6, 364-371.
36. Xue, W. et al. (2011) Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov., 1, 236-247.
37. Du, J. et al. (2011) Polymorphisms of nuclear factor-{kappa}B family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica, 96, 729-737.
38. Miyakoshi, S. et al. (2006) Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood, 107, 3492-3494.
39. Thiberville, L. et al. (2009) Human in vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur. Respir. J., 33, 974-985.
40. Rabe, K. F. et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med., 176, 532-555.
41. Lawrence, T. et al. (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med., 7, 1291-1297.
42. Greten, F. R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
43. Fong, C. H. et al. (2008) An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J. Exp. Med., 205, 1269-1276.
44. Hagemann, T. et al. (2008) " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med., 205, 1261-1268.
45. Cheng, D. S. et al. (2007) Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J. Immunol., 178, 6504-6513.
46. Han, W. et al. (2009) Myeloid cells control termination of lung inflammation through the NF-{kappa}B pathway. Am. J. Physiol. Lung Cell. Mol. Physiol., 296, L320-L327.